VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients.
European heart journal. Cardiovascular pharmacotherapy, 10(2): 89-90 PMID 38142221 DOI 10.1093/ehjcvp/pvad103
Abstract
This article has no abstract in PubMed.